drugset / Trial / NCT03254849

Empagliflozin and Sympathetic Nerve Traffic

NCT03254849

Phase 4 Completed 75 enrolled Profil Institute for Metabolic Research GmbH
RandomizedParallel-groupTriple-blindTreatment

Summary

In this study the effects of the Inhibition of the Sodium-Glucose Linked Transporter 2 in the kidney with empagliflozin compared to hydrochlorothiazide on blood pressure and on central sympathic nervous activity will be examined.

Timeline

Start
2017-12-08
Primary completion
2020-04-20
Completion
2020-04-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Empagliflozin Small molecule 25 mg Oral
Subject Hydrochlorothiazide Unknown 25 mg Oral